PDD-LAmB also stimulated APCs to elicit a Th1 response against this intracellular pathogen, as indicated by a marked transient lymphadenopathy, and an increase in the MHC II expression and interferon (IFN) γ induction in the PDD-LAmB-treated group. The gene discussed is GRAMD1B; the disease is Lymphadenopathy.